Heron Therapeutics | HRTX - Ordinary Share Capital


Heron Therapeutics reported $188.31M in Ordinary Share Capital for its fiscal quarter ending in December of 2025.





Ordinary Share Capital Change Date
ALKERMES USD 166.46M 855K Mar/2026
Alnylam Pharmaceuticals USD 133.44M 1.07M Mar/2026
Amarin USD 20.81M 13K Dec/2025
ANI Pharmaceuticals USD 22.49M 760K Dec/2025
Anika Therapeutics USD 13.89M 532K Dec/2025
Arrowhead Research USD 137.39M 1.69M Dec/2025
Eisai JPY 282.11M 0 Mar/2026
Emergent BioSolutions USD 100K 0 Jun/2023
Esperion Therapeutics USD 245.22M 39.79M Dec/2025
GlaxoSmithKline GBP 4.05B 20.6M Mar/2026
Heron Therapeutics USD 188.31M 4.99M Dec/2025
Insmed USD 216.52M 2.27M Mar/2026
Ligand Pharmaceuticals USD 19.66M 19.64M Sep/2025
Merck USD 2.47B 12.72M Dec/2025
Nektar Therapeutics USD 20.38M 20.36M Dec/2025
Neurocrine Biosciences USD 100.6M 500K Mar/2026
Omeros USD 611K 17K Dec/2023
Pacira USD 39.31M 1.81M Mar/2026
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 795.62M 699.54K Dec/2025
Surmodics USD 14.3M 13.58M Jun/2025
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Veracyte USD 79.79M 743K Mar/2026
Vertex Pharmaceuticals USD 254.2M 200K Mar/2026